{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T07:27:18Z","timestamp":1794122838837,"version":"4.8.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Antigenically drifted influenza A(H3N2) J.2.4.1 (subclade K) viruses predominated during the 2025-2026 Northern Hemisphere influenza season.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe influenza activity and burden, characterize subclade K, evaluate susceptibility to influenza antivirals and postinfluenza vaccination antibodies, and estimate vaccine effectiveness.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This surveillance study used multiple data sources, including (1) national surveillance of influenza-positive respiratory specimens collected by approximately 300 clinical laboratories and 100 public health laboratories from October 1, 2025, through March 14, 2026, a subset of which were further characterized; (2) serologic data of people who received 2025-2026 influenza vaccines; (3) influenza admissions data from the Influenza Hospitalization Surveillance Network (ie, 10% of US population) and the associated estimates of US burden; and (4) test-negative, case-control vaccine effectiveness estimates from the Virtual SARS-CoV-2, Influenza, and Other Respiratory Viruses Network.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Influenza infection, hospitalization, and vaccination.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes included influenza virus type, subtype, and clade; antiviral susceptibility; immunogenicity; influenza-associated outpatient and emergency department visits, hospitalizations, and mortality; estimated influenza illnesses, hospitalizations, and death; and estimated vaccine effectiveness.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n As of March 14, 2026, of the 55\u202f318 influenza-positive respiratory specimens tested by public health laboratories, most (50\u202f291 specimens [90.9%]) were influenza A, of which 40\u202f779 (81.1%) were subtyped and 35\u202f801 (87.8%) were A(H3N2). Of the 1754 characterized A(H3N2) viruses, most (1626 specimens [92.7%]) were subclade K. Postinfluenza vaccination neutralizing geometric mean antibody titers against subclade K were reduced 1.62 (95% CI, 1.29-2.02)\u2013fold compared with the vaccine virus. All 1729 tested A(H3N2) viruses were sensitive to antivirals. Of the 27\u202f881 recorded influenza hospitalizations, 15\u202f426 (54.7%) were among female patients, and 15\u202f051 (54.0%) were among patients aged 65 years or older. The estimated cumulative influenza-associated hospitalization rate was 80.0 per 100\u202f000 which would correlate with estimates of between 28\u202f000\u202f000 to 49\u202f000\u202f000 illnesses, 360\u202f000 to 740\u202f000 hospitalizations, and 22\u202f000 to 74\u202f000 deaths in the US during the 2025-2026 season. Adjusted interim vaccine effectiveness estimates against influenza-associated emergency department or urgent care encounters and hospitalizations were 35% (95% CI, 33%-38%) and 27% (95% CI, 21%-34%), respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This surveillance study found that while antigenically drifted viruses predominated and caused substantial morbidity and mortality, influenza vaccines were associated with a reduced risk of influenza among those who were vaccinated, and recommended antivirals remained effective.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.18581","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:30:35Z","timestamp":1781710235000},"page":"e2618581","source":"Crossref","is-referenced-by-count":7,"title":["Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season"],"prefix":"10.1001","volume":"9","author":[{"given":"Eduardo","family":"Azziz-Baumgartner","sequence":"first","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Budd","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Danielle","family":"Iuliano","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha R.","family":"Ellington","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Z.","family":"Levine","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Gubareva","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Adams","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"DeCuir","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Bozio","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Reed","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie K.","family":"Kirby","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rambo-Martin","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferson M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Biggerstaff","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Garg","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Todd","family":"Davis","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Burns","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kondor","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja J.","family":"Olsen","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien G.","family":"Dugan","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"VISION Coauthors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Irving","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Naleway","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Dascomb","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Sheffield","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah"},{"name":"Immunization Programs, Intermountain Health, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini B.","family":"DeSilva","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Y.","family":"Tartof","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena"},{"name":"Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina S.","family":"Sy","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousseny","family":"Zerbo","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun J.","family":"Grannis","sequence":"additional","affiliation":[{"name":"Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana"},{"name":"School of Medicine, Indiana University Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana"},{"name":"Fairbanks School of Public Health, Indiana University, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.","family":"Stockwell","sequence":"additional","affiliation":[{"name":"Division of Child and Adolescent Health, Department of Pediatrics, Columbia University, New York, New York"},{"name":"New York-Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Division of Child and Adolescent Health, Department of Pediatrics, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toan C.","family":"Ong","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Barron","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah W.","family":"Ball","sequence":"additional","affiliation":[{"name":"Westat, Inc, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Weber","sequence":"additional","affiliation":[{"name":"Westat, Inc, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L.","family":"Reeves","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Ray","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"7","key":"zoi260517r1","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3201\/eid2407.180028","article-title":"Mapping of the US domestic influenza virologic surveillance landscape.","volume":"24","author":"Jester","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"zoi260517r3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2471\/BLT.21.287253","article-title":"United States Centers for Disease Control and Prevention support for influenza surveillance, 2013-2021.","volume":"100","author":"McCarron","year":"2022","journal-title":"Bull World Health Organ"},{"issue":"49","key":"zoi260517r4","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.49.2500894","article-title":"Extended influenza seasons in Australia and New Zealand in 2025 due to the emergence of influenza A(H3N2) subclade K viruses.","volume":"30","author":"Dapat","year":"2025","journal-title":"Euro Surveill"},{"issue":"4","key":"zoi260517r6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jama.2025.25903","article-title":"Influzenza A (H3N2) subclade K virus: threat and response.","volume":"335","author":"Zambon","year":"2026","journal-title":"JAMA"},{"issue":"46","key":"zoi260517r7","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.46.2500854","article-title":"Early influenza virus characterisation and vaccine effectiveness in England in autumn 2025, a period dominated by influenza A(H3N2) subclade K.","volume":"30","author":"Kirsebom","year":"2025","journal-title":"Euro Surveill"},{"key":"zoi260517r13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.antiviral.2016.01.009","article-title":"Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.","volume":"128","author":"Okomo-Adhiambo","year":"2016","journal-title":"Antiviral Res"},{"key":"zoi260517r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105457","article-title":"An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance.","volume":"208","author":"Patel","year":"2022","journal-title":"Antiviral Res"},{"issue":"5","key":"zoi260517r15","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/aje\/kwx334","article-title":"Systematic assessment of multiple routine and near real-time indicators to classify the severity of influenza seasons and pandemics in the United States, 2003-2004 through 2015-2016.","volume":"187","author":"Biggerstaff","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi260517r17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.15585\/mmwr.mm7406a2","article-title":"Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness\u2014four vaccine effectiveness networks, United States, October 2024-February 2025.","volume":"74","author":"Frutos","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi260517r18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/cid\/ciae597","article-title":"Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States.","volume":"81","author":"Tenforde","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"129","key":"zoi260517r19","doi-asserted-by":"publisher","first-page":"56448","DOI":"10.3791\/56448","article-title":"Measuring influenza neutralizing antibody responses to A(H3N2) viruses in human sera by microneutralization assays using MDCK-SIAT1 cells.","author":"Gross","year":"2017","journal-title":"J Vis Exp"},{"issue":"32","key":"zoi260517r20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.15585\/mmwr.mm7432a2","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices\u2014United States, 2025-26 influenza season.","volume":"74","author":"Grohskopf","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi260517r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2026.108552","article-title":"Northern hemisphere 2025\/26 influenza vaccine effectiveness during months with influenza A(H3N2) subclade K predominance\u2014Suzhou, Eastern China.","volume":"167","author":"Cui","year":"2026","journal-title":"Int J Infect Dis"},{"issue":"1","key":"zoi260517r24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"zoi260517r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7706a1","article-title":"Laboratory-confirmed influenza-associated hospitalizations among children and adults\u2014influenza hospitalization surveillance network, United States, 2010-2023.","volume":"73","author":"Naquin","year":"2024","journal-title":"MMWR Surveill Summ"},{"issue":"8","key":"zoi260517r30","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.vaccine.2021.01.032","article-title":"Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009\/10 influenza pandemic.","volume":"39","author":"Okoli","year":"2021","journal-title":"Vaccine"},{"key":"zoi260517r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.128040","article-title":"Population effects of influenza vaccination in children and adolescents: systematic review.","volume":"71","author":"Askar","year":"2026","journal-title":"Vaccine"},{"key":"zoi260517r2","unstructured":"Centers for Disease Control and Prevention. Influenza virus genome sequencing and genetic characterization. Published September 17, 2024. Accessed February 2, 2026. https:\/\/www.cdc.gov\/flu\/php\/viruses\/genetic-characterization.html"},{"key":"zoi260517r5","unstructured":"Japan Institute for Health Security. Infectious agents surveillance report (in Japanese). Accessed February 4, 2026. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON586"},{"key":"zoi260517r8","unstructured":"Centers for Disease Control and Prevention. FluView. Accessed March 25, 2026. https:\/\/www.cdc.gov\/fluview\/index.html"},{"key":"zoi260517r9","unstructured":"Association of Public Health Laboratories. Influenza virologic surveillance right size roadmap. Published October 2022. Accessed January 27, 2026. https:\/\/aphl.org\/docs\/default-source\/technical\/ID-Influenza-Right-Size-Roadmap-Edition2.pdf"},{"key":"zoi260517r10","unstructured":"Neher? R, Huddle? JH. A\/H3N2 influenza viruses HA segment repository summary of designated subclades. Accessed January 27, 2026. https:\/\/github.com\/influenza-clade-nomenclature\/seasonal_A-H3N2_HA\/blob\/main\/.auto-generated\/subclades.md"},{"key":"zoi260517r11","unstructured":"Centers for Disease Control and Prevention. Antigenic characterization. Published September 17, 2024. Accessed January 27, 2026. https:\/\/www.cdc.gov\/flu\/php\/viruses\/antigenic.html"},{"key":"zoi260517r12","unstructured":"World Health Organization. Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs). Published March 7, 2023. Accessed January 27, 2026. https:\/\/www.who.int\/publications\/m\/item\/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais)"},{"key":"zoi260517r16","unstructured":"United States Food and Drug Administration. Influenza vaccine composition for the 2025-2026 U.S. influenza season. Updated March 13, 2025. Accessed January 27, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/influenza-vaccine-composition-2025-2026-us-influenza-season"},{"key":"zoi260517r21","unstructured":"Centers for Disease Control and Prevention. U.S. influenza surveillance: purpose and methods. Published December 2, 2025. Accessed March 24, 2026. https:\/\/www.cdc.gov\/fluview\/overview\/index.html#cdc_generic_section_3-outpatient-illness-surveillance"},{"key":"zoi260517r22","unstructured":"United States Centers for Disease Control and Prevention. 2025-2026 United States flu season: preliminary in-season severity assessment. Updated May 1, 2026. Accessed May 11, 2026. https:\/\/www.cdc.gov\/flu\/php\/surveillance\/in-season-severity.html"},{"key":"zoi260517r26","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2025-2026 northern hemisphere influenza season. Published February 28, 2025. Accessed January 27, 2026. https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-northern-hemisphere-recommendation-2025-2026\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2025-2026-northern-hemisphere-influenza-season.pdf"},{"key":"zoi260517r27","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2026 southern hemisphere influenza season. Published September 26, 2025. Accessed January 27, 2026. https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-sh-2025\/a.-26-september-2025-recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2026-southern-hemisphere-influenza-season---full-report.pdf"},{"key":"zoi260517r28","unstructured":"Centers for Disease Control and Prevention. Influenza activity in the United States during the 2024-25 season and composition of the 2025-26 influenza vaccine. Published September 26, 2025. Accessed January 27, 2026. https:\/\/www.cdc.gov\/flu\/whats-new\/2025-2026-influenza-activity.html"},{"key":"zoi260517r29","unstructured":"Centers for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness studies. Published March 16, 2026. Accessed March 25, 2026. https:\/\/www.cdc.gov\/flu-vaccines-work\/php\/effectiveness-studies\/index.html"},{"key":"zoi260517r31","doi-asserted-by":"crossref","unstructured":"Hassel? N, Marcenac? P, Bationo? CS, . Defining influenza epidemic zones through temporal clustering of global surveillance data.? medRxiv. Preprint posted online April 25, 2026. doi:10.64898\/2026.04.17.26351048","DOI":"10.2139\/ssrn.6094038"},{"key":"zoi260517r33","unstructured":"Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Updated March 10, 2026. Accessed May 11, 2026. https:\/\/www.cdc.gov\/flu\/hcp\/antivirals\/summary-clinicians.html"},{"key":"zoi260517r34","unstructured":"Centers for Disease Control and Prevention. People at increased risk for flu complications. Published September 11, 2024. Accessed February 4, 2026. https:\/\/www.cdc.gov\/flu\/highrisk\/index.htm"},{"key":"zoi260517r35","unstructured":"Association of Public Health Laboratories. 2025-26 Influenza season: surveillance for seasonal influenza and novel influenza A viruses. Accessed January 27, 2026. https:\/\/aphl.org\/resources\/resource-detail\/surveillance-for-seasonal-influenza-and-novel-influenza-a-viruses"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850461\/azzizbaumgartner_2026_oi_260517_1781030116.57772.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:30:47Z","timestamp":1781710247000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.18581","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}